Unlikely to cause harm — often a labeling or packaging issue.
Subpotent Drug
| Distributed by / for | Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, United Stated |
| NDC | 68180-904-11 |
| Full product label | Tydemy (drospirenone, ethinyl estradiol & levomefolate calcium tablets, 3 mg/0.03 mg/0.451 mg and levomefolate calcium tablets, 0.451 mg), packaged in cartons containing 3 wallets of 28 Tablets each, Rx Only, Distributed by: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, United Stated, Manufactured by: Lupin Limited, Pithampur, (M.P.) - 454775, India, 244896, The individual wallet NDC 68180-904-11 and the carton NDC 68180-904-13. |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Distribution | nationwide within the United States |
| Quantity | 4113 cartons |
| Recall initiated | 2021-11-19 |
| Report date | 2021-12-08 |
| Recall completed | 2022-11-15 |
| Recall number | D-0264-2022 |
| Classification | Class III |
| FDA status | Terminated |
| Origin on file | Baltimore MD United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗